WO2003099195A3 - Immunomodulatory compounds and methods of use thereof - Google Patents

Immunomodulatory compounds and methods of use thereof Download PDF

Info

Publication number
WO2003099195A3
WO2003099195A3 PCT/IB2003/003082 IB0303082W WO03099195A3 WO 2003099195 A3 WO2003099195 A3 WO 2003099195A3 IB 0303082 W IB0303082 W IB 0303082W WO 03099195 A3 WO03099195 A3 WO 03099195A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
immunomodulatory compounds
asthma
administering
directed
Prior art date
Application number
PCT/IB2003/003082
Other languages
French (fr)
Other versions
WO2003099195A2 (en
Inventor
Lynn D Hawkins
Sally T Ishizaka
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority to DE60325048T priority Critical patent/DE60325048D1/en
Priority to AU2003273171A priority patent/AU2003273171A1/en
Priority to EP03740968A priority patent/EP1511499B1/en
Priority to JP2004506722A priority patent/JP2005530805A/en
Publication of WO2003099195A2 publication Critical patent/WO2003099195A2/en
Publication of WO2003099195A3 publication Critical patent/WO2003099195A3/en
Priority to HK05107954.4A priority patent/HK1076713A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Abstract

The present invention is directed to methods of treating diseases and disorders related to immune responses by administering one or more immunomodulatory compounds. In particular, the invention is directed to methods of stimulating and reducing immune responses, treating autoimmune conditions, treating allergic reactions and asthma, and preventing ischemic damage and asthma by administering one or more immunomodulatory compounds.
PCT/IB2003/003082 2002-05-28 2003-05-28 Immunomodulatory compounds and methods of use thereof WO2003099195A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE60325048T DE60325048D1 (en) 2002-05-28 2003-05-28 IMMUNOMODULATIVE COMPOUNDS AND THE USE THEREOF
AU2003273171A AU2003273171A1 (en) 2002-05-28 2003-05-28 Immunomodulatory compounds and methods of use thereof
EP03740968A EP1511499B1 (en) 2002-05-28 2003-05-28 Immunomodulatory compounds and methods of use thereof
JP2004506722A JP2005530805A (en) 2002-05-28 2003-05-28 Immunomodulatory compounds and their use
HK05107954.4A HK1076713A1 (en) 2002-05-28 2005-09-09 Immunomodulatory compounds and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/157,791 2002-05-28
US10/157,791 US20040006242A1 (en) 1999-02-01 2002-05-28 Immunomodulatory compounds and method of use thereof

Publications (2)

Publication Number Publication Date
WO2003099195A2 WO2003099195A2 (en) 2003-12-04
WO2003099195A3 true WO2003099195A3 (en) 2004-10-07

Family

ID=29582541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/003082 WO2003099195A2 (en) 2002-05-28 2003-05-28 Immunomodulatory compounds and methods of use thereof

Country Status (9)

Country Link
US (2) US20040006242A1 (en)
EP (2) EP2039361A3 (en)
JP (1) JP2005530805A (en)
AT (1) ATE415974T1 (en)
AU (1) AU2003273171A1 (en)
DE (1) DE60325048D1 (en)
ES (1) ES2315511T3 (en)
HK (1) HK1076713A1 (en)
WO (1) WO2003099195A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835721B2 (en) * 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
ATE471328T1 (en) * 1999-02-01 2010-07-15 Eisai R&D Man Co Ltd COMPOUNDS WITH IMMUNOLOGICAL ADJUVANT EFFECT
JP2007514648A (en) 2003-10-24 2007-06-07 エーザイ株式会社 Compounds and methods for treating diseases and conditions associated with Toll-likereceptor2
ATE511859T1 (en) * 2004-07-20 2011-06-15 Schering Corp APOPTOSIS INDUCTION IN TOLL-LIKE RECEPTORS EXPRESSING TUMOR CELLS
AU2006226543B2 (en) 2005-03-23 2011-10-06 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce CD4 T-cell and/or improved B-memory cell response
US7976852B2 (en) * 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CN101213199B (en) * 2005-06-30 2013-12-18 卫材R&D管理有限公司 Compounds for preparing immunological adjuvant
FR2896162B1 (en) 2006-01-13 2008-02-15 Sanofi Pasteur Sa EMULSION OIL IN THERMOREVERSIBLE WATER
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
PE20090146A1 (en) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa IMMUNOGENIC COMPOSITION AGAINST THE INFLUENZA VIRUS
CA2710600C (en) 2007-12-24 2017-06-06 Id Biomedical Corporation Of Quebec Recombinant rsv antigens
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
US20110293660A1 (en) 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
US9265821B2 (en) 2009-02-17 2016-02-23 Glaxosmithkline Biologicals Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
PE20121541A1 (en) 2009-06-24 2012-12-21 Glaxosmithkline Biolog Sa RECOMBINANT RESPIRATORY SYNCIZAL VIRUS ANTIGENS
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
CA2774555A1 (en) 2009-09-25 2011-03-31 Glaxosmithkline Biologicals S.A. Immunodiffusion assay for influenza virus
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
EP2539365A4 (en) 2010-02-25 2015-03-25 Univ Duke Method of inducing the production of protective anti-hiv-1 antibodies
US20130039943A1 (en) 2010-05-03 2013-02-14 Bruno Rene Andre Novel method
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
ES2748651T3 (en) 2010-12-14 2020-03-17 Glaxosmithkline Biologicals Sa Antigenic composition of mycobacteria
CN103501811B (en) 2011-01-13 2016-03-30 变异生物技术公司 Be used for the treatment of compositions and the method for viral infection
US9434753B2 (en) 2011-09-19 2016-09-06 Gencia Corporation Modified creatine compounds
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US20150110824A1 (en) 2012-03-18 2015-04-23 Glaxosmithkline Biologicals, Sa Method of vaccination against human papillomavirus
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
WO2014140166A2 (en) 2013-03-15 2014-09-18 Glaxosmithkline Biologicals S.A. Vaccine
CA2953747A1 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CN105555304A (en) 2013-08-05 2016-05-04 葛兰素史密丝克莱恩生物有限公司 Combination immunogenic compositions
BE1022132B1 (en) 2013-08-30 2016-02-19 Glaxosmithkline Biologicals S.A. NEW METHOD.
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
AU2015209575A1 (en) * 2014-01-21 2016-07-21 Immune Design Corp. Compositions for use in the treatment of allergic conditions
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
WO2016140702A1 (en) 2015-03-03 2016-09-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces Display platform from bacterial spore coat proteins
CA3000591A1 (en) 2015-10-13 2017-04-20 Sanofi Pasteur Immunogenic compositions against s. aureus
TW201735952A (en) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 Amino acid and peptide conjugates and conjugation process
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
BE1025160B1 (en) 2016-12-07 2018-11-26 Glaxosmithkline Biologicals Sa NEW PROCESS
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
BR112019021824A2 (en) 2017-04-19 2020-06-02 Institute For Research In Biomedicine VACCINES AGAINST MALARIA AND PLASMODE SPOROZOYTE BINDING ANTIBODIES
EP3615061A1 (en) 2017-04-28 2020-03-04 GlaxoSmithKline Biologicals S.A. Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
BR112020004747A2 (en) 2017-09-13 2020-09-24 Sanofi Pasteur immunogenic composition of human cytomegalovirus
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
WO2021245025A1 (en) 2020-06-01 2021-12-09 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
IL303334A (en) 2020-12-02 2023-07-01 Glaxosmithkline Biologicals Sa Donor strand complemented fimh
WO2023114727A1 (en) 2021-12-13 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044758A1 (en) * 1999-02-01 2000-08-03 Eisai Co., Ltd. Immunological adjuvant compound
WO2001090129A2 (en) * 2000-05-19 2001-11-29 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
WO2002009752A2 (en) * 2000-07-31 2002-02-07 Eisai Co., Ltd. Immunological adjuvant compounds
WO2003011223A2 (en) * 2001-07-31 2003-02-13 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030621A (en) 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
JPH06104789B2 (en) 1989-03-31 1994-12-21 日本ペイント株式会社 Metal pigment composition and aqueous coating composition containing the same
WO1993004672A1 (en) 1991-09-11 1993-03-18 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
US5530113A (en) 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5484911A (en) 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5904925A (en) 1993-12-09 1999-05-18 Exner; Heinrich Adjuvant for antigens, and process for making
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE19511276C2 (en) 1995-03-27 1999-02-18 Immuno Ag Adjuvant based on colloidal iron compounds
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US5750664A (en) * 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
CA2223179A1 (en) 1995-06-07 1996-12-19 Bob Dale Brown Phosphonic acid-based cationic lipids
TW343975B (en) 1995-12-15 1998-11-01 Boehringer Mannheim Gmbh New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
US6284267B1 (en) * 1996-08-14 2001-09-04 Nutrimed Biotech Amphiphilic materials and liposome formulations thereof
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2330610A1 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
DE60016205T2 (en) 1999-05-28 2005-12-01 Vical, Inc., San Diego CYTOFECTIN DIMERS AND METHOD FOR THEIR USE
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
WO2001079299A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
EP1458242A4 (en) 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer Polyvalent conjugate vaccine for cancer
TWI248610B (en) * 2003-04-07 2006-02-01 Mediatek Inc Method and related apparatus for deriving a tracking error signal
US20070292418A1 (en) 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
US7976852B2 (en) * 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
CN101213199B (en) * 2005-06-30 2013-12-18 卫材R&D管理有限公司 Compounds for preparing immunological adjuvant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044758A1 (en) * 1999-02-01 2000-08-03 Eisai Co., Ltd. Immunological adjuvant compound
WO2001090129A2 (en) * 2000-05-19 2001-11-29 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
WO2002009752A2 (en) * 2000-07-31 2002-02-07 Eisai Co., Ltd. Immunological adjuvant compounds
WO2003011223A2 (en) * 2001-07-31 2003-02-13 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEUNG C.W. ET AL: "American Chemical Society - 226th National Meeting: New drugs highlights: 7-11 September 2003, New York, NY, USA.", IDRUGS, (2003) 6/10 (939-942)., XP008030540 *
HAWKINS, LYNN D. ET AL: "A novel class of endotoxin receptor agonists with simplified structure, toll -like receptor 4-dependent immunostimulatory action and adjuvant activity", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002), 300(2), 655-661, XP001189225 *
JIANG Z.-H. ET AL: "Synthetic vaccines: The role of adjuvants in immune targeting.", CURRENT MEDICINAL CHEMISTRY, (2003) 10/15 (1423-1439)., XP009017277 *
LIEN, EGIL ET AL: "A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/ toll -like receptor 4 signaling pathway", JOURNAL OF BIOLOGICAL CHEMISTRY (2001), 276(3), 1873-1880, XP002961151 *
PRZETAK, MELINDA ET AL: "Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice", VACCINE (2003), 21(9-10), 961-970, XP004402624 *

Also Published As

Publication number Publication date
HK1076713A1 (en) 2006-01-27
AU2003273171A8 (en) 2005-11-03
JP2005530805A (en) 2005-10-13
US20040006242A1 (en) 2004-01-08
ATE415974T1 (en) 2008-12-15
US20050164988A1 (en) 2005-07-28
WO2003099195A2 (en) 2003-12-04
US7833993B2 (en) 2010-11-16
EP2039361A3 (en) 2010-01-13
DE60325048D1 (en) 2009-01-15
AU2003273171A1 (en) 2003-12-12
ES2315511T3 (en) 2009-04-01
EP1511499A2 (en) 2005-03-09
EP2039361A2 (en) 2009-03-25
EP1511499B1 (en) 2008-12-03

Similar Documents

Publication Publication Date Title
WO2003099195A3 (en) Immunomodulatory compounds and methods of use thereof
WO2001090129A3 (en) Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
IL132293A0 (en) Use of lactoferin in the treatment of allergen induced disorders
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2001013906A3 (en) Compositions including modafinil for treatment of eating disorders and for appetite stimulation
AU2003239474A1 (en) Device and method for the treatment of cardiac disorders
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004106492A3 (en) Bicyclicpyrimidones and their use to treat diseases
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
AU2003286567A1 (en) Methods for the treatment of skin disorders
WO2005097119A3 (en) Pten inhibitors
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
EP1560593A4 (en) Novel composition and methods for the treatment of immune related diseases
AU2001243219A1 (en) Methods of prevention and treatment of asthma, and allergic conditions
WO2003084560A3 (en) Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
AU2002350254A1 (en) Novel carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
WO2004031105A3 (en) Use of a33 antigens and jam-it
WO2005074579A3 (en) Peptide mixtures with immunomodulatory activity
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
WO2004024063A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004073607A3 (en) Use of steroids to treat ocular disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004506722

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003740968

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003740968

Country of ref document: EP